Analytical Data
-
基因名
GUCY2C
-
简介
GUCY2C, a guanylyl cyclase, catalyzes cGMP synthesis from GTP and acts as a receptor for E. coli heat-stable enterotoxin, stimulating cGMP accumulation in expressing mammalian cells. Additionally, endogenous peptides guanylin and uroguanylin activate GUCY2C. This multifaceted role underscores intricate regulatory mechanisms in cellular signaling and GUCY2C's responsiveness to various stimuli, as confirmed by studies. GUCY2C/Guanylyl cyclase C Protein, Human (HEK293, His) is the recombinant human-derived GUCY2C/Guanylyl cyclase C protein, expressed by HEK293, with C-His labeled tag.
- Application
-
别名
Guanylyl cyclase C; GC-C; STAR; GUCY2C; GUC2C; STA receptor; DIAR6; EC 4.6.1; GCC; GUC2CEC 4.6.1.2; MUCIL
-
种属
Human
-
表达系统
HEK293
-
标签
C-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P25092
-
表达区间
S24-Q430
-
分子量
55-85 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GUCY2C (Guanylate Cyclase 2C) is a receptor guanylate cyclase primarily expressed in the intestinal epithelium, playing a crucial role in regulating electrolyte and fluid homeostasis. Its activation by endogenous ligands, such as natriuretic peptides and the guanylin family, leads to the conversion of GTP to cGMP, which subsequently triggers a cascade of intracellular signaling pathways affecting gut motility and secretion. Given its significant role in gastrointestinal physiology, GUCY2C has garnered attention as a potential therapeutic target for various gastrointestinal disorders, including irritable bowel syndrome and colorectal cancer. Researchers are focusing on the biochemical characterization and structural analysis of recombinant GUCY2C protein to better understand its function and regulatory mechanisms. Such studies may pave the way for the development of novel pharmacological agents that modulate GUCY2C activity, leading to improved treatments for related diseases. Furthermore, the production of recombinant GUCY2C facilitates high-throughput screening of small molecules and biologicals, enabling the identification of new modulators that could enhance or inhibit its signaling. The exploration of GUCY2C’s signaling pathways may not only illuminate its role in normal physiology but also its contributions to the pathophysiology of colorectal cancer, where it is often downregulated. Thus, the investigation of GUCY2C and its recombinant forms is critical for advancing our understanding of gut health and developing innovative therapeutic strategies.
